Advances in Cancer Immunology and Immunotherapy

Dear Colleagues,

Cancer remains one of the most deadly diseases in the world and a barrier to a longer life expectancy. According to the World Health Organization (WHO), cancer caused nearly 10 million deaths in 2020; approximately one in every six deaths. The overall survival rate after treatment varies among different types of cancers. Prostate cancer, melanoma, and female breast cancer are among those with the highest survival rates. Meanwhile, pancreas, liver, esophagus, and lung cancer are among those with the lowest. There is still a large amount of room for improving current studies on tumor immunology. By understanding the genetic and environmental factors that contribute to the development and elimination of cancer, more effective novel therapies can be achieved; patient outcomes and quality of life can also be improved.

Cancer immunotherapy has shown significant success in recent years; however, the limitations of current cancer immunotherapy are also obvious. Cancer immunotherapy is not always effective because of various reasons, such as cancer types and patients’ genetic backgrounds. Expensive costs and potential side effects are other problems that limit the applicability of cancer immunotherapy.

Discuss recent discoveries in tumor immunology as well as immunotherapy and the insights of those discoveries for further therapies. You are welcome to contribute a novel report, observation, or review article that focuses on (i) recent discoveries in tumor immunology and immunotherapy, (ii) a mechanistic explanation of the limitations of current tumor studies and immunotherapy, (iii) how to translate current knowledge into further therapies, (iv) future directions of tumor immunology studies, and (v) novel techniques as well as models which can help future tumor immunology studies. Update the community on the latest progress in tumor immunology as well as immunotherapy and point out future directions for researchers.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: tumor immunology, immunotherapy, and novel tumor models.

We look forward to receiving your contributions. 

Dr. Wenjie Jin
Dr. Zihe Huo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• tumor immunology
• immunotherapy
• efficiency and safety of immunotherapy
• novel tumor models
• ontogenesis